Document is current

Any future updates will be listed below

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Crossref DOI link: https://doi.org/10.1007/s40120-023-00463-y

Published Online: 2023-03-31

Published Print: 2023-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark